The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Lung cancer remains the leading cause of cancer ... To investigate the origins of LUSC, the team labeled Krt5-expressing basal cells in the trachea of two groups of mice so that the descendants ...

The test processes whole-slide images of non-small cell lung cancer tissue to provide a quantitative TROP2 score, which Roche says provides a level of precision beyond manual methods. TROP2 has ...

Popcorn lung can also be triggered by inhaling other ... we could avoid repeating the same mistakes. Regulations, clear labelling, stricter ingredient testing, and educational campaigns can ...